Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients

Nalesnik, Michael A.; Rao, Abdul S.; Zeevi, Adriana; Fung, John J.; Pharn, S.; Furukawa, Hiro; Gritsch, Albin; Klein, George; Starzl, Thomas E.

doi:10.1016/s0041-1345(96)00112-1

Cited by 19 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…76, 2002 PRIMARY IMMUNE REGULATION OF EBV TRANSFORMATION 5079 CD4 ϩ T-cell cytotoxic response was required for optimum activation of the NK cell component (51,52). Several studies with humans have highlighted the cytotoxic activity of CD4 ϩ T cells following stimulation by EBV-transformed LCL in seropositive adults (22,31,33,50) and in fetal cord blood (29,46,50). In contrast, other studies have shown that under certain circumstances CD4 ϩ T cells can enhance EBV reactivation by CD40/CD40 ligand-mediated signals (20).…”

Section: T Cells and Cd8mentioning

confidence: 99%

“…In vivo, following culture of peripheral blood lymphocytes in medium containing IL-2, the resultant lymphokine-activated killer cells are able to regulate the outgrowth of EBV-associated posttransplant lymphomas in humans (33). In murine models, NK cells activated in the presence of IL-2 up-regulated CD95 ligand and acquired the ability to kill CD95-positive tumor cells (10,26).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Primary Immune Responses by Cord Blood CD4⁺T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro

Wilson

Morgan

2002

J Virol

View full text Add to dashboard Cite

Section: T Cells and Cd8mentioning

confidence: 99%

mentioning

confidence: 99%

Primary Immune Responses by Cord Blood CD4⁺T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro

Wilson

Morgan

2002

J Virol

View full text Add to dashboard Cite

“…New/Novel Therapies Immunotherapeutic strategies have been investigated in PTLD, including use of autologous immune cells and the generation of EBV-specific T cells. Nalesnik et al [52] examined immunotherapy with autologous lymphokineactivated killer cells. Seven PTLD patients were treated with ex vivo autologous mononuclear cells cultured in the presence of interleukin-2; they noted several tumor responses.…”

Section: Cns Ptldmentioning

confidence: 99%

Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

et al. 2010

View full text Add to dashboard Cite

Post-transplantation lymphoproliferative disorders (PTLD) are a heterogenous group of abnormal lymphoid proliferations that occur after solid organ transplant (SOT) or hematopoietic transplantation. PTLDs consist of a disease spectrum ranging from hyperplasia to aggressive lymphomas with 60-70% being Epstein-Barr virus positive. The majority of cases are B-cell, although 10-15% are of T-cell origin or rarely Hodgkin lymphoma. Recent SOT series suggest PTLD occurs at a median of 36-40 months after transplant. Clinically, extra-nodal disease is common (up to 75-85%) including CNS involvement, which is seen in 10-15% of all cases. Since the first report over 40 years ago, PTLD has remained one of the most morbid complications associated with SOT. However, recent data suggests improved survival in the modern era, especially with the integration of early rituximab-based therapy. These studies utilized first line rituximab (+/- chemotherapy) together with reduced immune suppression (RI) for monomorphic and polymorphic PTLD. It will be critical in future studies to determine which PTLDs are most amenable to initial therapy with RI alone, versus RI/rituximab, versus RI/rituximab/chemotherapy. Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored.

show abstract

“…All the four patients with EBV-positive tumors sustained involution of their tumors; two patients suffered organ rejection as a complication of this therapy. 60 More recently, three patients donated T cells prior to solid-organ transplantation. EBV-specific cell lines were cultured and reinfused into the patients after transplant as PTLD prophylaxis.…”

Section: Cellular Immunotherapymentioning

confidence: 99%

Post-transplant lymphoproliferative disorder: a review

Loren

Porter

Stadtmauer

et al. 2003

Bone Marrow Transplant

247

201

View full text Add to dashboard Cite

Summary:Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of Epstein-Barr virus-related (EBV) clinical diseases, from a benign mononucleosis-like illness to a fulminant non-Hodgkin's lymphoma. In the setting of hematopoietic stem cell transplantation, PTLD is an often-fatal complication occurring relatively early after transplant. Risk factors for the development of PTLD are well established, and include HLA-mismatching, T-cell depletion, and the use of antilymphocyte antibodies as conditioning or treatment of graft-versushost disease. Early recognition of PTLD is particularly important in the SCT setting, because PTLD in these patients tends to be rapidly progressive. Familiarity with the clinical features of PTLD and a heightened level of suspicion are critical for making the diagnosis. Surveillance techniques with EBV antibody titers and/or polymerase chain raction (PCR) may have a role in some highrisk settings. Immune-based therapies such as monoclonal anti-B-cell antibodies, interferon-a, and EBV-specific donor T cells, either as treatment for PTLD or as prophylaxis in high-risk patients, represent promising new directions in the treatment of this disease.

show abstract

Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients

Cited by 19 publications

References 36 publications

Primary Immune Responses by Cord Blood CD4⁺T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro

Primary Immune Responses by Cord Blood CD4⁺T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro

Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

Post-transplant lymphoproliferative disorder: a review

Contact Info

Product

Resources

About

Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients

Cited by 19 publications

References 36 publications

Primary Immune Responses by Cord Blood CD4+T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro

Primary Immune Responses by Cord Blood CD4+T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro

Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

Post-transplant lymphoproliferative disorder: a review

Contact Info

Product

Resources

About

Primary Immune Responses by Cord Blood CD4⁺T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro

Primary Immune Responses by Cord Blood CD4⁺T Cells and NK Cells Inhibit Epstein-Barr Virus B-Cell Transformation In Vitro